Relacorilant shows significant benefits in Cushing’s patients in trial
About five months of treatment with relacorilant significantly reduced both high blood pressure and high blood sugar levels in people with endogenous Cushing’s syndrome, according to data from a Phase 3 trial. Relacorilant also was found to be generally safe and well tolerated, and to be able to significantly…